metricas
covid
Buscar en
Vacunas (English Edition)
Toda la web
Inicio Vacunas (English Edition) Prevalence of HCV among patients with HIV in Iran: A systematic review and meta-...
Journal Information
Vol. 25. Issue 1.
Pages 128-139 (January - March 2024)
Share
Share
Download PDF
More article options
Vol. 25. Issue 1.
Pages 128-139 (January - March 2024)
Review article
Prevalence of HCV among patients with HIV in Iran: A systematic review and meta-analysis
Maedeh Hajizadeha, Maryam Moradi Binabajb, Arezoo Asadic, Milad Abdid, Abolfazl Shakibae, Masoumeh Beigf, Mohsen Heidaryg,
Corresponding author
mohsenheidary40@gmail.com

Corresponding authors.
, Mohammad Sholehf,
Corresponding author
mohammad.sholeh.mail@gmail.com

Corresponding authors.
a Student Research Committee, Sabzevar University of Medical Sciences, Sabzevar, Iran
b Non-Communicable Diseases Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran
c Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran
d Research Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran
e Leishmaniasis Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran
f Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran
g Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (4)
Show moreShow less
Tables (1)
Table 1. Characteristics of fig articles in meta-analysis.
Abstract
Background

Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections are major public health issues worldwide. The present study aimed to estimate the prevalence of HCV among patients with HIV in Iran and evaluate the demographic and behavioral factors associated with a heterogeneity of results.

Methods

MEDLINE (via PubMed), Web of Science, SCOPUS, Google Scholar, Embase, and 2 Persian databases, including Scientific Information Database (SID) and Magiran, were used for a systematic search from January 1, 2005 to February 26, 2022. Data were analyzed according to country, publication time, enrolment time, number of patients, gender, mean age, HIV/HCV diagnosis method, and HIV/HCV treatment. The analysis was carried out using R and the metafor package.

Results

We found that 60.94 (95% CI 54.59–67.11) HIV-infected people in Iran were co-infected with HCV. The greatest burden of this co-infection was in the Hamedan 86.67 (62.12, 96.26), Kashan 85.71 (75.03, 92.30), followed by the Kerman 73.94(66.75, 80.04). The lowest prevalence of HBV-HCV co-infection was observed in Kermanshah at 11.91 (9.98, 13.98).

Conclusion

HBV-HCV co-infection is a challenging and important medical condition because of its variable clinical manifestations, increased risk of cirrhosis and HCC, and unpredictable treatment response. Due to the heterogeneous distribution pattern of HBV–HCV infection in Iran, continuous prevention and control measurements and the implementation of further epidemiologic studies are necessary.

Keywords:
Human immunodeficiency virus
HIV
Hepatitis C
HCV
Iran
Palabras clave:
Virus de la inmunodeficiencia humana
VIHVIH
hepatitis C
VHC
Irán
Resumen
Antecedentes

Las infecciones por el virus de la inmunodeficiencia humana (VIH) y el virus de la hepatitis C (VHC) son uno de los principales problemas de salud pública en el mundo. El objetivo del presente estudio fue El presente estudio tuvo como objetivo estimar la prevalencia de VHC entre pacientes con VIHVIH en Irán y evaluar los factores demográficos y de comportamiento asociados con una heterogeneidad de resultados.

Métodos

se utilizaron MEDLINE (a través de PubMed), Web of Science, SCOPUS, Google Scholar, Embase y 2 bases de datos persas, incluida la base de datos de información científica (SIDSID) y Magiran, para una búsqueda sistemática desde el 1 de enero de 2005 hasta el 26 de febrero de 2022. Los datos se analizaron según el país, el tiempo de publicación, el tiempo de inscripción, el número de pacientes, el sexo, la edad media, el método de diagnóstico del VIH/VHC y el tratamiento del VIH/VHC. El análisis se realizó mediante R y el paquete metafor. El análisis estadístico se realizó mediante STATA versión 14 (StataCorp, College Station, Texas).

Resultados

Encontramos que 60,94 (IC del 95%: 54,59 a 67,11) personas infectadas por el VIH en Irán estaban coinfectadas con el VHC. La mayor carga de esta coinfección estuvo en Hamedan 86.67 (62.12, 96.26), Kashan 85.71 (75.03, 92.30), seguido por Kerman 73.94 (66.75, 80.04). La prevalencia más baja de coinfección VHB-VHC se observó en Kermanshah con 11,91 (9, 13, 98).

Conclusión

La coinfección VHB-VHC es una condición médica desafiante e importante debido a sus manifestaciones clínicas variables, mayor riesgo de cirrosis y CHC, y respuesta impredecible al tratamiento. Debido al patrón heterogéneo de distribución de la infección por VHB-VHC en Irán, es necesario realizar medidas continuas de prevención y control y realizar más estudios epidemiológicos.

Article

These are the options to access the full texts of the publication Vacunas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Vacunas (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos